PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 130 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2016. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $7,847,000 | -55.4% | 255,602 | -2.5% | 0.98% | -55.4% |
Q3 2016 | $17,586,000 | +110.1% | 262,286 | -6.7% | 2.21% | +86.0% |
Q2 2016 | $8,371,000 | +43.3% | 280,985 | +41.3% | 1.19% | +54.1% |
Q1 2016 | $5,840,000 | -53.0% | 198,859 | +25.5% | 0.77% | -47.2% |
Q4 2015 | $12,424,000 | +20.3% | 158,475 | +15.6% | 1.46% | +22.0% |
Q3 2015 | $10,327,000 | -37.3% | 137,041 | -2.9% | 1.20% | -28.5% |
Q2 2015 | $16,476,000 | -51.8% | 141,123 | -2.5% | 1.67% | -50.4% |
Q1 2015 | $34,170,000 | +44.6% | 144,721 | +15.9% | 3.37% | +53.9% |
Q4 2014 | $23,626,000 | -2.0% | 124,826 | +23.5% | 2.19% | -3.0% |
Q3 2014 | $24,109,000 | +133.2% | 101,055 | -35.5% | 2.26% | +145.3% |
Q2 2014 | $10,339,000 | -60.3% | 156,649 | -37.4% | 0.92% | -62.7% |
Q1 2014 | $26,066,000 | +4.3% | 250,296 | +3.7% | 2.47% | +7.0% |
Q4 2013 | $24,994,000 | +66.4% | 241,419 | -13.8% | 2.31% | +65.3% |
Q3 2013 | $15,021,000 | -0.8% | 279,926 | -18.0% | 1.40% | -11.8% |
Q2 2013 | $15,149,000 | – | 341,417 | – | 1.58% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,300,000 | $12,636,000 | 2.61% |
AIGH Capital Management LLC | 964,590 | $9,376,000 | 1.97% |
Worth Venture Partners, LLC | 226,758 | $2,204,000 | 1.07% |
Camber Capital Management LP | 2,555,000 | $24,835,000 | 0.85% |
Palo Alto Investors LP | 1,392,997 | $13,540,000 | 0.77% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,769,795 | $36,642,000 | 0.77% |
GLOBEFLEX CAPITAL L P | 428,680 | $4,167,000 | 0.76% |
Zebra Capital Management LLC | 34,243 | $333,000 | 0.37% |
Sofinnova Investments, Inc. | 344,917 | $3,353,000 | 0.20% |
RICE HALL JAMES & ASSOCIATES, LLC | 605,792 | $5,888,000 | 0.19% |